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Baltimore, MD, USAA B S T R A C TObjectives: We examine the associations of adherence to antiparkin-
son drugs (APDs) with health care utilization and economic outcomes
among patients with Parkinson’s disease (PD). Methods: By using
2006–2007 Medicare administrative data, we examined 7583 beneﬁ-
ciaries with PD who ﬁlled two or more APD prescriptions during 19
months (June 1, 2006, to December 31, 2007) in the Part D program.
Two adherence measures— duration of therapy (DOT) and medication
possession ratio (MPR)—were assessed. Negative binomial and
gamma generalized linear models were used to estimate the rate
ratios (RRs) of all-cause health care utilization and expenditures,
respectively, conditional upon adherence, adjusting for survival risk,
sample selection, and health-seeking behavior. Results: Approxi-
mately one-fourth of patients with PD had low adherence (MPR o
0.80, 28.7%) or had a short DOT (r400 days, 23.9%). Increasing
adherence to APD therapy was associated with decreased health care
utilization and expenditures. For example, compared with patients
with low adherence, those with high adherence (MPR ¼ 0.90–1.00) hadsee front matter Copyright & 2014, International S
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Building, 12th Floor, 220 Arch Street, Baltimore, Msigniﬁcantly lower rates of hospitalization (RR ¼ 0.86), emergency
room visits (RR ¼ 0.91), skilled nursing facility episodes (RR ¼ 0.67),
home health agency episodes (RR ¼ 0.83), physician visits (RR ¼ 0.93),
as well as lower total health care expenditures ($2242), measured
over 19 months. Similarly, lower total expenditure ($6308) was
observed in patients with a long DOT versus those with a
short DOT. Conclusions: In this nationally representative sample,
higher adherence to APDs and longer duration of use of APDs were
associated with lower all-cause health care utilization and total
health care expenditures. Our ﬁndings suggest the need for improving
medication-taking behaviors among patients with PD to reduce the
use of and expenditures for medical resources.
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Parkinson’s disease (PD), characterized by tremor, rigidity, and
bradykinesia, is the second most common neurodegenerative
disorder after Alzheimer’s disease in the United States [1]. This
disease predominantly affects people aged 60 years or older [2];
an estimated 1.6 million Medicare beneﬁciaries live with PD [3].
PD places substantial economic burden on patients and insurers,
and costs society on average $10.8 billion annually [4]. The cost of
PD is expected to increase with the aging baby boomers [5,6].
While there is no treatment to cure PD, or proven treatments
to slow down its progression, antiparkinson drugs (APDs) are
considered the mainstream approach to control motor symptoms
[7–9]. Despite the importance of taking APDs regularly and
consistently [10–13], evidence regarding adherence to theseagents among a representative sample of patients with PD is
limited. Studies of APD adherence were clinical-based studies
with small sample sizes and short observation periods [14–16].
Although two studies were conducted at the population level
[17,18], ﬁndings were limited to patients with PD in managed
care settings. Higher nonadherence rates were observed in
population-based studies (61%–67%) [17,18] compared with clin-
ical studies (12.0%–12.5%) [14–16], due to differences in the study
populations and how adherence was measured.
Patient adherence to prescribed APD regimens is critical for
optimal motor function, quality of life, and preventing the need
for more costly health care services, such as hosplitzation [13]. A
study of 3119 patients with PD enrolled in managed care plans
during 1997 to 2004 demonstrated that compared with good
adherers, poor adherers had more hospitalizations (2.3 vs. 1.8)ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
utical Health Services Research, University of Maryland School of
D 21201.
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Despite these ﬁndings, this study failed to account for many
potential confounders. For example, “healthy-user effect” has
been implicated as a source of bias because adherers tend to be
healthier or engage in health-seeking behaviors, thereby having
lower health care utilization and expenditures [19–22]. Other
potential confounders not yet addressed in studies include
physician specialty, the frequency of treatment changes (i.e.,
switching and augmentation), and whether patients live in
long-term care (LTC) facilities [13]. To address these gaps, this
study aimed to examine the prevalence of APD adherence and
the association of adherence with health care utilization and
expenditures while controlling for potential confounders among
a Medicare Part D population diagnosed with PD. The rationale
for this study was to have a better understanding of medication-
taking behaviors and their consequences through improving
upon previous studies’ methodological issues, as well as target-
ing population generalizable to Medicare Part D beneﬁciaries. Our
generalizable ﬁndings intend to assist clinicians and policy-
makers to appropriately target patients with PD with poor
adherence to APDs, and/or readjust clinical practices in the
Medicare Part D population with PD.Methods
Study Design and Data
We conducted a retrospective cross-sectional study by using the
2006–2007 Chronic Care Conditions Data Warehouse data that
represent a 5% random sample of Medicare beneﬁciaries [23]. The
Chronic Care Conditions Data Warehouse data include detailed
administrative claims for all Medicare Part A (inpatient), B (out-
patient), and D (prescription drug event) services. The ﬁrst 5
months (January 1, 2006, to May 31, 2006) served as baseline;
beneﬁciaries were followed for up to 19 months (June 1, 2006, to
December 31, 2007) or until death in 2007. We selected June 1,
2006, as the starting date to observe complete drug data for
patients enrolled in the Part D program when it went into effect
on January 1, 2006, and for those enrolled as late as May 15, 2006.
The conduct of this study was approved by the Institutional
Review Board of the University of Maryland Baltimore, Maryland.
Sample
Sample selection criteria included 1) having one or more claim
with a primary or secondary diagnosis of PD (International Classi-
ﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation codes 332.0)
in each of the years 2006 and 2007; 2) continuously enrolled in
Medicare Parts A, B, and a Prescription Drug Plan (PDP) through-
out the follow-up period (i.e., June 1, 2006, to December 31, 2007,
or death in 2007); and 3) having maintained Parts A and B
enrollments throughout baseline. We did not require beneﬁcia-
ries to maintain PDP enrollment throughout baseline because
nearly one-third (31.5%) of our sample was of late enrollees, a
group who enrolled in Part D in the early part of 2006 (i.e., January
1, 2006, to May 15, 2006) and thus did not have PDP enrollment in
each month of the baseline period. From these 9604 eligible
beneﬁciaries, we excluded patients who died in 2006 (n ¼ 36) to
ensure that each patient had at least a 7-month (June 1, 2006, to
December 31, 2006) drug observation window, as well as those
enrolled in Medicare Advantage/Health Maintenance Organiza-
tions because of lack of available medical and drug claims (n ¼
810), resulting in a sample of 8758 Medicare PDP enrollees with a
diagnosis of PD. Of these, 7706 (88%) used at least one APD,
assessed through Part D claims. We further limited this sample to
those with at least two Part D APD prescriptions ﬁlled at differenttime points (n ¼ 7583) to calculate medication adherence and
duration [24,25].
Measures
APD adherence measures
APDs approved by the Food and Drug Administration for the
treatment of PD were identiﬁed by using National Drug Codes.
The six major classes of APDs include dopamine precursors (e.g.,
levodopa), dopamine agonists, monoamine oxidase B inhibitors,
catechol-O-methyltransferase inhibitors, amantadine, and anti-
cholinergic agents [7,8]. We excluded three APDs: rotigotine
because of its short U.S. market life [26], apomorphine because
of rare use in clinical practice [7,8], and pergolide because of
withdrawal on March 29, 2007 [27].
Key independent variables included duration of therapy (DOT)
and medication possession ratio (MPR), two adherence measures
used to assess different components of medication-taking behav-
iors. DOT assesses the duration of time, or persistence that a
patient is treated with APDs, while MPR assesses how regularly
patients take APDs while in their possession [28]. DOT was
measured as the number of days between the ﬁrst and last ﬁlled
prescription of all APDs and the days’ supply of the last ﬁll, date
of death, or December 31, 2007, whichever came ﬁrst [24,25,29].
This DOT measure included a permissible gap of 30 or fewer days
between reﬁlls to allow for any residual effect of previous APDs
and any remaining medications stockpiled. More than two-thirds
(73%) of APD prescriptions ﬁlled by our sample were a 30 days’
supply. For assessing medication adherence, we used a modiﬁed
MPR, calculated as the total days’ supply from all APD classes
(numerator) divided by the aggregate DOT of all drug classes
(denominator) to avoid overestimation of MPR values for drug
classes ﬁlled concurrently [30]. The MPR numerator included
days’ supply carried over from prescriptions ﬁlled before June 1,
2006; in the denominator, we excluded Part A–covered hospital
and skilled nursing facility (SNF) days because of inability of the
data to discern medications taken during these periods [31].
Because DOT and MPR were highly negative skewed (more
than half of the patients had DOT Z 540 days and an MPR of
Z0.90), we analyzed these two measures as categorical variables
with cutoffs close to quartiles of the respective distribution: short
(r400 days), medium (401–539 days), long (540–578 days), and
maximum (579 days) DOT; low (r0.79), moderate (0.80–0.89), and
high (0.90–1.00) MPR. An MPR of greater than 1 was truncated at 1,
because it was the result of either early reﬁlls or exclusion of Part
A–covered days (hospital or SNF) from the denominator of MPR
calculation.
Outcomes: All-cause health care utilization and expenditures
Our dependent variables were all-cause health care utilization
and expenditures measured over the same time frame as adher-
ence. We assessed the total number of visits/episodes that each
patient made to each of the following ﬁve settings: hospital,
emergency room (ER), SNF, home health agency (HHA), and
physician ofﬁce. Expenditures for Medicare Part A, B, and D
services were calculated on the basis of payments from individ-
uals (e.g., deductibles and co-payment) and from Medicare and
non-Medicare programs (e.g., Veteran Administration). The costs
of Part A, B, and D services were summed to yield total expendi-
tures for each individual.
Covariates
We included an extensive set of covariates in this analysis to
control for confounding due to sociodemographic characteristics
(age, sex, race, and region), the timing of Part D enrollment (early
vs. late), Part D low-income subsidy status, whether seen by
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 1 9 6 – 2 0 4198neurologists, LTC stay, disease- and drug-related factors, general
health status, and use of preventive services. Early enrollees
enrolled in the Part D program before 2006, whereas late enrollees
joined between January 1, 2006, and May 15, 2006. Length of LTC
stay was measured in number of days for which patients resided
in either SNFs using Part A SNF claims or other LTC facilities
using Minimum Date Set assessment—a mandatory tool for
collecting data on residents in Medicare- or Medicaid-certiﬁed
nursing homes. We used claims-based International Classiﬁcation of
Diseases, Ninth Revision diagnoses to assess three disease-related
factors: depression (yes/no), cognitive disorders (measured by the
presence of three main diagnoses—Alzheimer’s disease, demen-
tia, and psychosis) [32,33], and overall comorbidities (measured
by hierarchical condition categories [34] excluding the above four
diseases).
Drug-related variables included medication burden (i.e., num-
bers of distinct medications) and changes in APD regimens (i.e.,
number of switches and augmentations). Switch was deﬁned as
starting a different APD to replace the previous one that was later
discontinued without any reﬁlls. Augmentation required adding a
different APD to an existing drug regimen. To ensure accuracy of
occurrences of augmentation, we required that both old and new
APDs be reﬁlled at least one time and that reﬁll periods must
overlap. General health status was proxied by two measures—
whether patients died in 2007 and health care utilization at
baseline. We used baseline hospitalizations in expenditure out-
come analyses; for each of the ﬁve utilization outcomes (hospital-
ization, ER, SNF, HHA, and physician visits), baseline utilization of
the respective medical service was measured. These utilization
parameters have been demonstrated to be signiﬁcantly associ-
ated with poor health status [35–37]. The measure of mortality
was also used to control for survival bias.
Use of four preventive services (inﬂuenza vaccinations, color-
ectal cancer screening, prostate cancer screening for males only,
and mammography screening or pap smears for females only)
was measured from June 1, 2006, to December 31, 2007, by using
Part B claims data to control for the effect of health-seeking
behaviors on medication adherence and outcomes [38]. We
selected these four services because 1) they were covered by
Medicare before and throughout the study period (2006–2007) and
2) most of the services (including inﬂuenza vaccinations, mam-
mograms, and pap smears) were recommended to be performed
annually [39]. A yearly prostate-speciﬁc antigen testing was
encouraged during our study period [40]. Colorectal cancer
screening, depending on the type of tool used, was recommended
every 10 years (colonoscopy), every 5 years (ﬂexible sigmoido-
scopy), or annually (fecal occult blood test) [39]. The frequency of
these selected services is higher than that of other nonselected
Medicare-covered preventive services (e.g., once per lifetime for
pneumococcal vaccine).
Statistical Analyses
Descriptive statistics were presented for sociodemographic and
clinical characteristics of the sample overall, and by the MPR
categories. We reported crude health care utilization prevalence
and rates (per patient-year) and health care expenditures (means
and SDs), overall and by DOT and MPR categories. Separate
negative binomial generalized linear models (GLMs) with adjust-
ment for covariates and two types of biases were used to
estimate rate ratios and 95% conﬁdence intervals for the associ-
ation of DOT and MPR with utilization rates for all ﬁve services.
We used gamma GLM to approximate the highly right-skewed
distribution of expenditure outcomes [41,42]. We converted the
coefﬁcients from the gamma GLM models to marginal effects (i.e.,
absolute dollar differences) with standard errors and P values.
When estimating the associations of DOT with utilization andexpenditure outcomes, we excluded patients with a maximum
DOT (579 days) because only 1% of these patients had hospital-
ization or SNF utilization. Estimates from this maximum DOT
group are likely to be biased because utilization has yet to occur.
Heckman Correction for Sample Selection Bias
To generalize our study results to the entire Medicare Part D
population, we corrected for sample selection bias inherent in
self-selection into PDP or Medicare-Advantage Prescription Plans
[43] by using Heckman’s two-stage procedures [44]. In the ﬁrst
stage, a probit model was used to predict the probability of
beneﬁciaries enrolling in a PDP as opposed to Medicare-
Advantage Prescription Plans among the entire 2006-2007 5%
Chronic Care Conditions Data Warehouse population with evi-
dence of Part D enrollment. Variables in the probit model to
predict the PDP enrollment included age, sex, race, residency,
death in 2007, and comorbidities. In addition to these factors, we
included two variables at the regional ZIP code level: 1) number of
different PDP plans available to beneﬁciaries, derived from 2006
Centers for Medicare & Medicaid Services Medicare Advantage
Landscape Source ﬁles [45] and 2) percentage of employees
offered health insurance, derived from the 2006 Medical Expen-
diture Panel Survey [46]. From the ﬁrst-stage probit model, we
generated an inverse Mills ratio that represents potential sample
selection bias; the inverse Mills ratio was then incorporated into
our multivariate regression models in the second stage [44].
All analyses were performed by using PROC GENMOD (SAS
version 9.2, SAS Institute, Inc., Cary, NC) and GLM (STATA version
11.1, Stata Corp., College Station, TX).Results
Our sample of 7583 beneﬁciaries with PD was predominantly older
than 65 years (93.6%), female (59.9%), white (89.3%), and early
enrollees (68.5%) (Table 1). More than half (51.1%) were low-income
subsidy eligible and more than two in three (69.6%) visited
neurologists during the study period. This Medicare PD sample
had high comorbidity: 39.0% had a diagnosis of depression, 62.2%
were cognitively impaired, and 52.4% had nine or more comorbid-
ities. Their medication burden was substantial, with half (50.0%)
using 13 or more medications. Almost half (46.3%) resided in SNFs
or other LTC facilities and did not engage in any of the studied
preventive services (46.4%). One in 5 (19.4%) had a baseline
hospitalization; more than 1 in 10 (13.7%) died during 2007.
Approximately a quarter had an MPR of less than 0.8 (28.7% ¼
2179 of 7583) or a DOT of 400 days or less (23.9%) over the period of
19 months (579 days). Across the three MPR groups, there were
statistically signiﬁcant differences in the majority of the measured
characteristics, including age, race, region, early Part D enrollment,
low-income subsidy status, whether seen by neurologists, cogni-
tive conditions, comorbidities, change in the APD regimen, LTC
stay, use of preventive services, death in 2007, and DOT.
Table 2 shows prevalence and crude rates of utilization out-
comes by DOT and MPR. Lower proportions of hospitalization
were observed among long DOT users (58.4%) than among short
and medium DOT users (66.4% and 69.0%, respectively), and
among high adherers (46.7%) than among low and moderate
adherers (56.6% and 56.7%, respectively). Similar patterns were
observed with hospitalization rates. Also, patients with long DOT
and high MPR had lower utilization of ER, SNF, and HHA than did
their less adherent and shorter duration peers. Patients with high
MPR also had fewer physician visits than did those with low MPR.
Mean total expenditures were lower in long DOT users
($32,472) than in short DOT users ($54,488), and the same pattern
was observed for Part A ($10,497 vs. $33,849) and Part B ($11,062
Table 1 – Distributions of demographic and clinical characteristics among 7583 Medicare Part D Prescription
Drug Plan enrollees with Parkinson’s disease (PD), and by different MPRs.
Characteristics Total sample MPR* P†
n % Low Moderate High
Patients 7583 100 2179 100 1456 100 3948 100
Age (y) o0.001
Mean  SD, median 77.2  8.9, 78.0 76.5  8.8, 77.0 77.1  9.1, 78.0 77.6  8.9, 79.0
r64 488 6.4 139 6.4 89 6.1 260 6.6
65–74 2074 27.4 673 30.9 426 29.3 975 24.7
75–84 3492 46.0 979 44.9 653 44.8 1860 47.1
85þ 1529 20.2 388 17.8 288 19.8 853 21.6
Sex 0.370
Female 4543 59.9 1279 58.7 874 60.0 2390 60.5
Male 3040 40.1 900 41.3 582 40.0 1558 39.5
Race o0.001
White 6775 89.3 1868 85.7 1316 90.4 3591 91.0
Black 382 5.1 156 7.2 65 4.5 161 4.1
Other‡ 426 5.6 155 7.1 75 5.2 196 5.0
Region o0.001
Northeast 1575 20.8 399 18.3 295 20.3 881 22.3
North Central 2075 27.4 532 24.4 359 24.7 1184 30.0
South 2847 37.5 913 41.9 583 40.0 1351 34.2
West 1086 14.3 335 15.4 219 15.0 532 13.5
Early vs. late enrollees o0.001
Early enrollees 5192 68.5 1394 64.0 1005 69.0 2793 70.7
Late enrollees 2391 31.5 785 36.0 451 31.0 1155 29.3
Low-income subsidy (LIS) status o0.001
LIS 3873 51.1 1017 46.7 720 49.5 2136 54.1
Non-LIS 3710 48.9 1162 53.3 736 50.5 1812 45.9
Seen by neurologists o0.001
Yes 5280 69.6 1631 74.9 1065 73.1 2584 65.5
No 2303 30.4 548 25.1 391 26.9 1364 34.5
Depression§ 0.161
Yes 2959 39.0 825 37.9 597 41.0 1537 38.9
No 4624 61.0 1354 62.1 859 59.0 2411 61.1
Number of cognitive conditions|| 0.008
Mean  SD, median 2.0  0.9, 2.0 2.0  0.9, 2.0 2.0  0.9, 2.0 2.0  0.9, 2.0
0 2865 37.8 850 39.0 531 36.5 1484 37.6
1 1810 23.9 465 21.3 347 23.8 998 25.3
2–3 2908 38.3 864 39.7 578 39.7 1466 37.1
Comorbid conditions o0.001
Mean  SD, median 8.8  3.1, 9.0 9.2  3.2, 9.0 9.0  3.2, 9.0 8.6  3.0, 8.0
1–6 1765 23.3 475 21.8 317 21.8 973 24.6
7–8 1845 24.3 470 21.6 332 22.8 1043 26.4
9–10 1786 23.6 494 22.7 358 24.6 934 23.7
11–22 2187 28.8 740 34.0 449 30.8 998 25.3
Number of non-PD drugs 0.084
Mean  SD, median 15.7  8.2, 14.0 15.7  8.2, 14.0 16.2  8.3, 15.0 15.5  8.1, 14.0
0–7 1811 23.0 525 24.1 329 22.6 957 24.2
8–12 2048 27.0 574 26.3 359 24.7 1115 28.2
13–18 1904 25.0 546 25.1 387 26.6 971 24.6
19–76 1820 25.0 534 24.5 381 26.2 905 22.9
Change in APD regimen o0.001
Mean  SD, median 1.3  0.6, 1.0 1.4  0.7, 1.0 1.4  0.7, 1.0 1.3  0.6, 1.0
0 5658 75.0 1543 70.8 1054 72.4 3088 78.2
1 1165 15.4 342 15.7 250 17.2 573 14.5
2–8 733 9.6 294 13.5 152 10.4 287 7.2
Length of long-term care stay (mo) o0.001
Mean  SD, median 12.7  18.3, 0.0 8.8  15.6, 0.0 12.2  17.8, 0.0 15.0  19.5, 0.0
0 4072 53.7 1307 60.0 762 52.3 2003 50.7
1–12 1645 21.7 532 24.4 356 24.5 754 19.1
13–19 1866 24.6 340 15.6 338 23.2 1191 30.2
Preventive services use o0.001
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Table 1 – continued
Characteristics Total sample MPR* P†
n % Low Moderate High
0 3516 46.4 904 41.5 661 45.4 1951 49.4
1 2934 38.7 929 42.6 559 38.4 1446 36.6
2–3 1133 14.9 346 15.9 236 16.2 551 14.0
Death in 2007 0.015
Yes 1037 13.7 262 12.0 196 13.5 579 14.7
No 6546 86.3 1917 88.0 1260 86.5 3369 85.3
Hospitalizations at baseline¶ 0.787
Yes 1471 19.4 429 19.7 288 19.8 754 19.1
No 6112 80.6 1750 80.3 1168 80.2 3194 80.9
Duration of therapy (d) o0.001
Mean  SD, median 472  137, 536 428  142, 469 490  113, 536 489  137, 563
Short (r400) 1813 23.9 763 35.0 257 17.7 793 20.1
Medium (401–539) 2061 27.2 767 35.2 490 33.7 804 20.4
Long (540–578) 2019 26.6 457 21.0 456 31.3 1106 28.0
Maximum (579) 1690 22.3 192 8.8 253 17.4 1245 31.5
APD, antiparkinson drugs; ICD-9, International Classiﬁcation of Diseases, Ninth Revision; MPR, medication possession ratio.
* Low MPR was deﬁned as o0.80, moderate MPR, 0.80–0.89, and high MPR, 0.90–1.00.
† Statistical signiﬁcance was tested with chi-squared tests.
‡ Other included Hispanic, Asian, the natives of North America, and individuals with other or unknown races and ethnicities.
§ ICD-9 codes used to deﬁne depression: 296.2x, 296.3x, 300.4, 309.1, and 311.
|| ICD-9 codes used to deﬁne cognitive conditions: Alzheimer’s disease (331.0), dementia (290.1-290.4, 294.1, 294.8, 331.1-331.2, 331.7, and 797),
and psychosis (293.81, 293.82, 298.0, 298.1, 298.4, 298.8, 298.9, 297.1, 368.16, and 780.1).
¶ Baseline ¼ January 1, 2006, to May 31, 2006.
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were higher in long DOT users ($10,913) than in short DOT users
($7,272). Similar expenditure ﬁndings were found in high adher-
ers relative to those with low and moderate MPR.
Unadjusted results showed signiﬁcant inverse associations of
DOT and MPR with all-cause health care utilization outcomes in
general (Table 2). After adjustment for covariates and sample
selection bias, a signiﬁcantly lower hospitalization rate was seen
for patients with a medium (rate ratio ¼ 0.83; 95% conﬁdence
interval ¼ 0.79–0.88; P o 0.001) and long (rate ratio ¼ 0.74; 95%
conﬁdence interval ¼ 0.69–0.78; P o 0.001) DOT than for patients
with a short DOT. Also, signiﬁcantly fewer ER visits and SNF
episodes were observed among the long DOT groups than among
the short DOT group. We also noted signiﬁcantly lower utilization
rates for all ﬁve health care services for high adherers, although
not for moderate adherers, than for low adherers.
After multivariate adjustment, signiﬁcantly lower total health
care expenditures were exhibited in long DOT users ($6,308, Po
0.001) than in short DOT users (Table 4). Total expenditure
reductions for patients with long DOT were driven by their
signiﬁcant decreases in Part A ($10,095, Po 0.001) expenditures.
Also, patients with high adherence to APDs had signiﬁcantly lower
expenditures in total ($2,242, Po 0.01), Part A ($6,941, Po 0.001),
and Part B ($848, P o 0.01) services, but higher Part D spending
($3,068, P o 0.001) than did patients with low adherence.Discussion
With a nationally representative sample of Medicare Part D
enrollees with PD, our data showed that more than two-thirds
had good adherence to APDs (i.e., an MPR of Z80%) and had a
treatment duration of at least 13 months over a 19-month period.
The percentage of good adherers (72.7%) in our PD sample of
Medicare Part D beneﬁciaries was higher than that in previous
studies in managed care populations with PD (ranging from 33.0%to 53.5%) [11,17,18]. This variation in adherence estimates may
also result from the different designation of PD. We deﬁned
patients with PD by using a method of ﬂagging International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation 332.0
codes in two consecutive years. This approach has a high
sensitivity of 89.2% and a moderate-to-high positive predictive
value of 79.4% in identifying true PD patients, compared with
medical chart review [47]. In contrast, other studies of APD
adherence identiﬁed patients with PD by using diagnostic codes
not speciﬁc to PD (332.1 [secondary parkinsonism], 333.0 [other
degenerative diseases of the basal ganglia], or 333.1 [tremor]), in
addition to 332.0 [11,17,18]. The use of these four codes jointly
had shown an unsatisfactory sensitivity (18.7%) in detecting
patients with PD as compared with medical chart view [48]. In
addition, APDs are effective treatment for patients with conﬁr-
matory PD diagnosis [7–9] but not for patients without PD (e.g.,
those with secondary parkinsonism or tremor) [7,8]. Taken
together, our chosen approach, compared with that used by
previous studies, is likely to identify a sample with a greater
proportion of true PD cases who have a higher likelihood of
taking APD treatment to control parkinsonism symptoms.
Accordingly, the APD adherence estimate observed from our PD
sample differed from that of previous studies. Also, our PD
enrollees had similar high adherence rates as Part D enrollees
with other chronic diseases [49].
This study also demonstrated clinical and economic beneﬁts
of persistent and regular APD use. Longer DOT and higher
adherence were signiﬁcantly associated with lower utilization
of acute (hospital and ER) and chronic (SNF and HHA) services for
any cause, while incurring no change or a decrease in routine
ofﬁce-based physician care. Also, optimal APD-taking behaviors
were associated with a signiﬁcant reduction in total health
expenditures. Although patients with longer DOT and higher
MPR had higher Part D medication expenditures, this increase
was more than offset by cost savings from reduced spending on
Part A and B services. This observation suggests that signiﬁcant
Table 2 – Descriptive statistics (prevalence and rate) and relative risks of all-cause health care utilization by
APDs’ adherence measures.
Medication
measures
Total
sample
Prevalence
(%)
Person-
years
Crude
rate*
Unadjusted RR
(95% CI)
Adjusted†,‡ RR
(95% CI)
Hospitalizations
DOT§ (d)
Short 1813 66.4 2072 1.40 1.00 1.00
Medium 2061 69.0 2968 1.16 0.77 (0.71–0.83)|| 0.83 (0.79–0.88)||
Long 2019 58.4 3297 0.69 0.44 (0.41–0.48)|| 0.74 (0.69–0.78)||
MPR¶
Low 2179 56.6 3332 0.93 1.00 1.00
Moderate 1456 56.7 2235 0.85 0.92 (0.84–1.01) 1.02 (0.96–1.08)
High 3948 46.7 5989 0.62 0.68 (0.63–0.74)|| 0.86 (0.81–0.90)||
Emergency room visits
DOT§ (d)
Short 1813 73.9 2072 1.81 1.00 1.00
Medium 2061 75.0 2968 1.55 0.80 (0.74–0.86)|| 0.88 (0.83–0.93)||
Long 2019 64.9 3297 1.10 0.57 (0.52–0.61)|| 0.87 (0.81–0.92)||
MPR¶
Low 2179 67.6 3332 1.34 1.00 1.00
Moderate 1456 65.7 2235 1.21 0.90 (0.83–0.98)# 0.95 (0.88–1.02)
High 3948 59.4 5989 1.01 0.76 (0.71–0.81)|| 0.91 (0.86–0.96)||
SNF episodes
DOT§ (d)
Short 1813 41.2 2072 1.52 1.00 1.00
Medium 2061 48.3 2968 1.39 0.85 (0.77–0.94)|| 0.94 (0.86–1.03)
Long 2019 14.4 3297 0.20 0.12 (0.10–0.13)|| 0.20 (0.18–0.23)||
MPR¶
Low 2179 31.7 3332 0.86 1.00 1.00
Moderate 1456 33.6 2235 0.86 0.99 (0.86–1.13) 1.19 (1.07–1.13)||
High 3948 24.3 5989 0.52 0.62 (0.55–0.69)|| 0.67 (0.61–0.73)||
Home health agency episodes
DOT§ (d)
Short 1813 34.8 2072 0.67 1.00 1.00
Medium 2061 37.0 2968 0.67 0.93 (0.83–1.04) 1.12 (1.02–1.23)#
Long 2019 32.3 3297 0.55 0.74 (0.66–0.83)|| 1.01 (0.91–1.12)
MPR¶
Low 2179 37.8 3332 0.65 1.00 1.00
Moderate 1456 31.7 2235 0.54 0.83 (0.73–0.93)** 0.91 (0.83–1.00)
High 3948 24.7 5989 0.42 0.65 (0.59–0.71)|| 0.83 (0.76–0.89)||
Ofﬁce-based physician visits
DOT§ (d)
Short 1813 90.2 2072 12.60 1.00 1.00
Medium 2061 92.8 2968 12.95 1.04 (0.97–1.11) 1.04 (0.97–1.11)
Long 2019 95.2 3297 14.82 1.12 (1.05–1.20)|| 1.12 (1.05–1.20)||
MPR¶
Low 2179 94.9 3332 15.24 1.00 1.00
Moderate 1456 92.7 2235 13.67 0.90 (0.83–0.96)** 0.94 (0.90–0.99)#
High 3948 90.8 5989 11.91 0.78 (0.74–0.83)|| 0.93 (0.89–0.97)||
APD, antiparkinson drugs; CI, conﬁdence interval; DOT, duration of therapy; IMR, inverse Miller’s ratio; LTC, long-term care; MPR, medication
possession ratio; RR, rate ratio; SNF, skilled nursing facility.
* Rate was calculated as utilization events per patient-year over 1.6 y (19 mo).
† Adjusted variables included demographic characteristics (age, sex, race, and residency), low-income subsidy status (yes/no), early/late Part D
enrolment, whether seen by neurologists, depression (yes/no), number of cognitive conditions, comorbidities, drug burden, changes in APD
therapy, preventive services use, LTC stay, utilization outcome of interest at baseline (January 1, 2006, to May 31, 2006), and IMR. IMR was
statistically signiﬁcant (P o 0.05) in all ﬁve utilization outcome models, suggesting the presence of sample selection bias.
‡ The length of LTC stay was controlled in all models, but not for SNF outcome models because of a high correction between LTC stay and SNF
utilization.
§ Short DOT was deﬁned as r400 d, medium DOT, 401–539 d, and long DOT, 540–578 d.
|| P o 0.001.
¶ Low MPR was deﬁned as o0.80, moderate MPR, 0.80–0.89, high MPR, 0.90–0.99, and optimal MPR, 1.00
# P o 0.05.
** P o 0.01.
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Table 3 – Mean and SD of health care expenditures by antiparkinson drugs’ adherence measures.
Medication measures Total expenditures Part A expenditures Part B expenditures Part D expenditures
Total sample 40,471  38,838 19,216  29,968 11,264  12,624 9,991  10,401
DOT* (d)
Short 54,488  51,937 33,849  41,331 13,367  16,156 7,272  9,131
Medium 52,782  40,819 29,458  30,634 13,103  12,347 10,221  10,788
Long 32,472  23,397 10,497  14,146 11,062  11,937 10,913  8,086
MPR†
Low 45,867  44,582 24,727  34,910 12,889  14,842 8,251  6,937
Moderate 43,417  38,643 21,603  30,392 11,838  12,226 9,976  7,966
High 36,407  34,850 15,294  26,036 10,155  11,255 10,957  12,460
DOT, duration of therapy; MPR, medication possession ratio.
* Short DOT was deﬁned as r400 d, medium DOT, 401–539 d, and long DOT, 540–578 d.
† Low MPR was deﬁned as o0.80, moderate MPR, 0.80–0.89, and high MPR, 0.90–1.00
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 1 9 6 – 2 0 4202reductions in health care utilization and expenditures could be
achieved by improved duration of use and adherence to APDs. It
is worth noting that 70% (723 of 1037) of the patients who died in
2007 were classiﬁed as short DOT users. These deceased patients
who incurred no further costs after death might have skewed
cost estimates of the short DOT group toward having lower
health care cost. Despite this artifact of lower health care costs
in the short DOT group, their expenditures were observed to be
higher than those of medium and long DOT groups. Our ﬁndings
remained unchanged even after the exclusion of all deceasedTable 4 – Unadjusted and adjusted* association of DOT a
expenditures.
Adherence
measures
Total expenditures Part A expenditu
Marginal
effect ($)
Standard
error
Marginal
effect ($)
Sta
err
DOT† (d)
Unadjusted
Short (referent) 0.00 0.00
Medium 1,738 1,517 4,424‡ 1
Long 22,048‡ 1,328 23,386‡ 1
Adjusted
Short (referent) 0.00 0.00
Medium 940 1,177 3,110§ 1
Long 6,308‡ 1,266 10,095‡ 1
MPR||
Unadjusted
Low (referent) 0.00 0.00
Moderate 2,451 1,392 3,124¶ 1
High 9,461‡ 1,104 9,433‡
Adjusted
Low (referent) 0.00 0.00
Moderate 85 948 2,935 1
High 2,242¶ 790 6,941‡ 1
DOT, duration of therapy; IMR, inverse Miller’s ratio; MPR, medication p
* Adjusted variables included demographic characteristics (age, sex, r
enrolment, whether seen by neurologists, depression, number of cognit
drugs therapy, preventive service use, long-term care stay, death in 20
2006), and IMR. IMR was statistically signiﬁcant (P o 0.05) in all four
selection bias.
† Short DOT was deﬁned as r400 d, medium DOT, 401–539 days, and lo
‡ P o 0.001.
§ P o 0.05.
|| Low MPR was deﬁned as o 0.80, moderate MPR, 0.80–0.89, and high MP
¶ P o 0.01.patients from analysis (e.g., marginal effect for total expenditure
¼ –$7,895, long vs. short DOT groups, P o 0.001; data not shown).
Our study measured patients’ medication-taking behaviors
from two domains— DOT and adherence. These two measures
yielded similar patterns, attesting to the robustness of our
ﬁndings. From a clinical perspective, medication adherence
may affect all-cause health care utilization and expenditures
through two pathways. First, improved APD adherence alleviates
PD symptoms and maintains motor function. Second, patients
with improved APD adherence may follow the same healthynd medication adherence with all-cause health care
res Part B expenditures Part D expenditures
ndard
or
Marginal
effect ($)
Standard
error
Marginal
effect ($)
Standard
error
0.00 0.00
,183 265 467 2,951‡ 320
,022 2,305‡ 464 3,643‡ 280
0.00 0.00
,352 63 376 2,444‡ 326
,431 350 444 3,749‡ 348
0.00 0.00
,092 1,051§ 451 1,724‡ 256
855 2,734‡ 365 2,706‡ 248
0.00 0.00
,539 439 343 1,483‡ 211
,307 848† 292 3,068‡ 241
ossession ratio.
ace, and residency), low-income subsidy status, early/late Part D
ive conditions, comorbidities, drug burden, changes in antiparkinson
07, all-cause hospitalizations at baseline (January 1, 2006, to May 31,
expenditure outcome models, suggesting the presence of sample
ng DOT, 540–578 d.
R, 0.90–1.00.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 1 9 6 – 2 0 4 203behavior pattern by adhering to drug therapy for other chronic
conditions. This “healthy behavior” effect, manifested as cross-
over adherence from one therapeutic class as a predictor of
improved adherence to other therapeutic classes used for other
comorbidities, has been demonstrated in separate studies focus-
ing on patients with osteoporosis and depression [50,51].
Our study analyzed DOT and MPR as categorical variables in
an attempt to provide more nuanced and informative insights on
DOT and MPR distributions, as well as to elucidate the nature of
the relationships between categorical measures of DOT and MPR
and outcomes. The cutoffs used for DOT and MPR groups,
however, do not necessarily reﬂect clinical outcomes. Also, to
our knowledge, there is no consensus on the clinically mean-
ingful threshold of duration of adherence to APDs, although an
MPR of 0.8 or more has been commonly used in previous APD
studies [14,16–18]. In addition, we measured medication adher-
ence during a reﬁll interval, rather than a ﬁxed time period. The
ﬁxed period likely results in an artiﬁcially inﬂated time period by
including days when APDs were not much in need for patients
with early-stage PD with mild motor symptoms, or days when
APDs became unwanted because of their ineffectiveness in the
advanced stage of PD. To avoid a possible inﬂation in the treat-
ment period, we used the reﬁll interval, a period during which
APDs were prescribed and reﬁlled for symptom control, to
provide accurate estimates of adherence to APDs.
Our study is among the ﬁrst examining a wide spectrum of
utilization outcomes, from routine physician care, acute care, to
chronic care, using patients with PD. Also, through correction of
sample selection bias, we were able to generalize our ﬁndings to
Medicare Part D enrollees with PD, although not to beneﬁciaries
who did not enroll in Part D. The non-Part D group, most of whom
are beneﬁciaries with drug creditable plans, tended to be health-
ier, than Part D enrollees [52]. Thus, when applied to non-Part D
enrollees, our ﬁnding should be interpreted cautiously.
Nevertheless, our population-level, generalizable data are useful
for health insurers (e.g., Centers for Medicare & Medicaid Serv-
ices) in planning interventions to reduce a wide range of pre-
ventable procedures, and to further generate health care cost
savings.
Several limitations of this study should be noted. First,
administrative claims do not have information on general health
status and PD severity. We addressed the limitation of general
health status for PD by controlling for mortality and baseline
utilization in regression models. Furthermore, we conducted a
post hoc analysis by using institutionalized status as a proxy of
PD severity [53]. The analysis showed similar ﬁndings between
patients with and without LTC stay (data not shown), suggesting
that the confounding effect from PD severity might be minimal.
Second, there is no direct measure of cognitive status in admin-
istrative claims. We were able, however, to measure the presence
of dementia, Alzheimer’s disease, and psychosis to deﬁne cogni-
tive function, as suggested in previous studies [33,54,55]. Third,
prescription claims data do not detail drug response and toler-
ability. We proxied these factors by using the occurrences of
medication switching and/or augmentations based on clinical
observations that changes in APDs often occur among patients
with poorer response or tolerance to these drugs [7,56]. Fourth,
we excluded days of Part A–covered hospital and SNF services
from DOT calculation, and this might have led to overestimation
of the association of DOT with hospitalizations and SNFs. Never-
theless, the potential effect may be limited because only a small
proportion of Part A–covered days was excluded from the total
follow-up days (1.2% ¼ 45,388 of 3,802,527 for hospital days; 2.2%
¼ 82,312 of 3,802,527 for SNF days; data now shown). Last, we
were unable to account for other potential confounders, such as
education and income levels, patients’ beliefs on APD use, or
surgical intervention with deep brain stimulation (DBS) becauseof administrative data limitations. Patients with PD with high
level of education, high income, and strong beliefs on medication
use tended to adhere to the medications [16,57], but might have
lower health care utilization and/or medical expenditures than
do their counterparts. Thus, the omission of these variables
might have attenuated the magnitude of associations observed.
Patients with PD who underwent DBS (vs. those without) might
have higher utilization and medical costs resulting from the
surgical procedure and postoperative care. While these surgery
patients tended to be less dependent on APDs [58], their tendency
to adhere to the medications was unknown. Thus, omitting DBS
in our analyses could have either attenuated or augmented our
ﬁndings.
Despite our cross-sectional design that cannot assess causal-
ity, our study provides signiﬁcant evidence that improved adher-
ence can potentially reduce health care outcomes. Our next step
is to apply these criteria over a longer period by using longitudi-
nal data to conﬁrm causal relationships between medication use
and outcomes in a Medicare population. In addition, it is crucial
to understand the effect of Part D policies, such as Medication
Therapy Management and beneﬁt design, on patients’
medication-taking behaviors, and consequent effects on health
outcomes and spending in this population.
In conclusion, more than two-thirds of beneﬁciaries with PD
are persistent and adherent with APDs. Higher adherence and
longer duration of APD medications were associated with lower
utilization of acute and chronic care, as well as lower expendi-
tures for total, Part A, and Part B services. This study provided
population-based evidence to clinicians and policymakers regard-
ing the importance of improving medication duration and adher-
ence to APDs among patients with PD. Interventions designed to
enhance medication-taking behaviors for patients with PD are
needed to avoid health care utilization and generate medical
savings.
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